81 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
. Previously, she served as President of MedImmune, LLC, at AstraZeneca plc’s global biologics research and development unit, and Executive Vice President … for Biochemistry in Germany. We believe Dr. Jallal’s extensive experience in the biotechnology industry, leading drug research and development
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
) melanoma, IMC-F106C, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, and IMC-I109V, and our research and development programs, including delays or disruptions … (or ocular) melanoma, IMC-F106C, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, and IMC-I109V, and our research and development programs, including delays
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
January 2019. Previously, she served as President of MedImmune, LLC, at AstraZeneca plc’s global biologics research and development unit … of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
(or ocular) melanoma, IMC-F106C, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, and IMC-I109V, and our research and development programs, including delays … research and development programs, including delays or disruptions in clinical trials, non-clinical experiments and investigational new drug application
8-K
EX-99.2
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
of Research & Development Innovating for sustainable growth Maximizing potential of KIMMTRAK Advancing clinical portfolio 11
PRAME is negative … Innovating for sustainable growth David Berman Head of Research & Development 17
18 Platform candidates NOW across 3 therapeutic areas Oncology ImmTAC
8-K
EX-99.1
fze90hf9
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
fjzhq4l7vahef7m
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
sj1k 7ynexd
28 Feb 24
Annual report
7:33am
8-K
e2j2ems8dif3ym kh37
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
6-K
EX-99.2
zpidurg6fl7p04qbo
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
qdx77gm pinuq0
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
mlg3ekv0
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
whxfhdbto686
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
1ua8y1ta7q
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
063q83gi 79yd6ijmo
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
mkw1 843wku781es
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
8aqbql
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
f4o2fd4fkht
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
630ic6256dcpo1wjce4n
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
01cy2 u40x54
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm